Funding for this research was provided by:
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
Accepted: 25 May 2021
First Online: 8 June 2021
: All authors have seen and approved the publication.
: MF and RKG are shareholders of Rodos Biotarget GmbH, which holds intellectual propriety rights on the company’s targeted nanocarrier technology. All other authors declare no conflict of interest.